이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Herantis Pharma Oyj 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Antti Vuolanto

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2yrs
CEO 소유권	0.01%
경영진 평균 재임 기간	3.8yrs
이사회 평균 재임 기간	3.3yrs

최근 관리 업데이트

Recent updates

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Mar 06

CEO

Antti Vuolanto (49 yo)

2yrs

테뉴어

Dr. Antti Vuolanto, D.Sc. (Tech) serves as Chief Executive Officer of Herantis Pharma Oyj since July 2022. He served as Chief Operating Officer at Herantis Pharma Oyj since February 2018. Dr. Vuolanto serv...

리더십 팀

이름	위치	테뉴어	보상	소유권
Antti Vuolanto	Chief Executive Officer	2yrs	데이터 없음	0.012% € 3.8k
Tone Kvale	Chief Financial Officer	3.8yrs	데이터 없음	0.056% € 18.0k
Henri Huttunen	Chief Scientific Officer	14.4yrs	데이터 없음	0.40% € 128.2k
Jani Koskinen	Head of CMC	no data	데이터 없음	데이터 없음
Outi Lahdenperä	Chief Medical Ofcer	no data	데이터 없음	데이터 없음
Charlotte Videbaek	Clinical Consultant	no data	데이터 없음	데이터 없음

3.8yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: HRTIS 의 관리팀은 경험 ( 3.7 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Aki Prihti	Director	10.5yrs	데이터 없음	0.0079% € 2.6k
Anders Pedersen	Chairman of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Timo Veromaa	Independent Chairman of the Board	12.5yrs	데이터 없음	0.076% € 24.6k
Mats Thoren	Director	4.3yrs	데이터 없음	데이터 없음
Frans Wuite	Director	10.5yrs	데이터 없음	0.14% € 44.0k
Alberto Espay	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Hilde Furberg	Director	3.3yrs	데이터 없음	0.0099% € 3.2k
David Dexter	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음
Daniele Bravi	Member of Scientific Advisory Board	2.8yrs	데이터 없음	데이터 없음

3.3yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: HRTIS 의 이사회는 경험(평균 재직 기간 3.2 년)으로 간주됩니다.

Herantis Pharma Oyj 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Less than half of directors are independent

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Oyj Announces Nomination Committee Appointments

Recent updates

Herantis Pharma Oyj to Report Fiscal Year 2023 Results on Mar 27, 2024

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €4.506795 million.

Herantis Pharma Plc Announces Positive Topline Data from Phase 1a Clinical Trial of HER-096

Herantis Pharma plc Announces First Healthy Volunteers Dosed in the Part 2 of the Her-096 Phase 1A Clinical Study

Herantis Pharma Plc Announces Start of Recruitment of Healthy Volunteers for Part 2 of the Ongoing Phase 1a Clinical Study of HER-096

Herantis Pharma Oyj Announces Submission of A Clinical Trial Application (CTA) for A Phase 1 Study for HER-096

Herantis Pharma Oyj to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Herantis Pharma Applies for Delisting from Nasdaq First North Growth Market Sweden

Less than half of directors are independent

Herantis Pharma Oyj to Report Second Half, 2022 Results on Mar 02, 2023

Herantis Pharma plc Announces Executive Changes

Less than half of directors are independent

Herantis Pharma Oyj has completed a Follow-on Equity Offering in the amount of €1.4625 million.

Herantis to Focus on HER-096

High number of new and inexperienced directors

High number of new and inexperienced directors

Herantis Pharma Announces Successful rhCDNF Results With Nanoform Technology

Herantis Pharma Announces xCDNF Preclinical Candidate Selection

Earnings beat expectations

Herantis Pharma Oyj (HEL:HRTIS) Is About To Turn The Corner

Herantis Pharma Plc Announces Inconclusive Results from Phase II Study with Lymfactin in Breast Cancer Related Lymphedema

New 90-day low: €3.28

Herantis Pharma Oyj and Nanoform Enter into Agreement for Proof of Concept Collaboration

Herantis Pharma Oyj Announces Nomination Committee Appointments

Herantis Pharma plc Appoints Magnus Sjögren as Chief Medical Officer, Effective May 1, 2021

Herantis Pharma Oyj to Report Fiscal Year 2020 Final Results on Mar 25, 2021

New 90-day low: €3.90

Herantis Pharma Plc and Nanoform Finland Plc Signs Letter of Intent for Collaboration

Herantis Pharma Announces Favorable 24-Month Follow-Up Review from Phase I Lymfactin® Trial in Breast Cancer Associated Lymphedema

New 90-day low: €4.83

Ingrid Heiman to Leave Herantis Pharma's Board of Directors

Herantis Pharma Plc Appoints Tone Kvåle as Member of the Management Team

New 90-day low: €6.82

New 90-day low: €7.24

Herantis Pharma Oyj to Report Fiscal Year 2020 Results on Mar 03, 2021

New 90-day high - €8.86

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령